News & Events
Hydrexia named in 2013 Global Cleantech Top 100, and winner of Asia Pacific company of the year
17 / 10 / 2013
Celladon Corporation Announces Publication of Follow-Up Results from the MYDICAR CUPID 1 Trial
26 / 09 / 2013
Neurovance Announces FDA Acceptance of IND Application for EB-1020 and Initiates Study in Adult ADHD
24 / 09 / 2013
KaloBiosā?? KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
19 / 09 / 2013
Human Safety and PK/PD Data from Phase 1 Study of KB001 Supports Ongoing Phase 2 Clinical Trial of KB001-A in Cystic Fibrosis
Sunshine Heart Implants First Patient in C-Pulse(R) COUNTER HF(TM) U.S. Pivotal Trial
13 / 09 / 2013
Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board
10 / 09 / 2013
National - Telstra Australian Business Awards: Health.com.au
23 / 08 / 2013
Health.com.au has been awarded Telstraā??s National Business of the year award in the Start- Up category, after winning the Telstra Victorian Start- Up of the year in July.
Cowen: Four EU C-Pulse Patients Implanted; U.S. Enrollment On Tap
08 / 08 / 2013
We reiterate our Outperform rating on Sunshine Heart primarily due to our view that the C-Pulse could prove to be a disruptive solution for NYHA Class III and IV ambulatory CHF patients.
Cannacord Genuity: Solid progress across the board; maintain 12.50PT and reiterate buy
08 / 08 / 2013
Sunshine Heart announced solid progress in trial site enrollment in both the US and Europe. During the quarter, the company activated three new sites for the COUNTER HF US pivotal trial, activated two new sitesfor the OPTIONS HF EU post -market study, and has made significant progress in its product development efforts. In the US, SSH is on track to activate a total of 22 centers by year end and eight centers in Europe,both in line with our expectations. Reimbursement efforts are tracking to plan in both regions, and early data from the first four C - Pulse implants in Europe validate the potential benefits of this device demonstrated in the feasibility trial.
Elastagen and Endoluminal Sciences secure $4.5m funding from NSW Health Medical Devices Fund
01 / 08 / 2013
Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR reverse PAH
30 / 07 / 2013
KaloBios Provides Update on Pipeline of Clinical Programs
28 / 06 / 2013
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of its ongoing clinical programs for KB003, KB001-A and KB004, its pipeline of proprietary monoclonal antibodies in development for severe respiratory diseases and cancer.